Therapeutic angiogenesis in the heart: protect and serve

Current Opinion in Pharmacology

Volumn 7, Issue 2, 2007, Pages 158-163

  Molin, Daniel ^a   Post, Mark J ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; CHEMOKINE; CYTOKINE; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEPARIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR BB; POLYMER; PR 39; PROTEIN DEL 1; SCATTER FACTOR; SCLEROPROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN 189; VASCULOTROPIN A; VIRUS VECTOR; ZINC FINGER PROTEIN;

ANGIOGENESIS; ARTERY DISEASE; CLINICAL TRIAL; COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG TARGETING; EXTRACELLULAR MATRIX; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

ANGIOGENESIS INDUCING AGENTS; CORONARY DISEASE; CORONARY VESSELS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYOCARDIAL REPERFUSION INJURY; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES;

EID: 33947109490     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.10.006     Document Type: Review

References (44)

1. Cao Y., Hong A., Schulten H., and Post M.J. Update on therapeutic neovascularization. Cardiovasc Res 65 (2005) 639-648
2. Hoefer I.E., Piek J.J., and Pasterkamp G. Pharmaceutical interventions to influence arteriogenesis: new concepts to treat ischemic heart disease. Curr Med Chem 13 (2006) 979-987
3. Annex B.H., and Simons M. Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovasc Res 65 (2005) 649-655
4. Ye L., Haider H., and Sim E.K. Adult stem cells for cardiac repair: a choice between skeletal myoblasts and bone marrow stem cells. Exp Biol Med (Maywood) 231 (2006) 8-19
5. Kloeckner J., Prasmickaite L., Hogset A., Berg K., and Wagner E. Photochemically enhanced gene delivery of EGF receptor-targeted DNA polyplexes. J Drug Target 12 (2004) 205-213
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936. This a comprehensive and detailed review of molecular circuits that are involved in neovascularization in health and disease by one of the leaders in angiogenesis research.
7. Heissig B., Rafii S., Akiyama H., Ohki Y., Sato Y., Rafael T., Zhu Z., Hicklin D.J., Okumura K., Ogawa H., et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med 202 (2005) 739-750
8. Gerhardt H., and Betsholtz C. How do endothelial cells orientate?. EXS (2005) 3-15. This review gives an extremely thoughtful insight into the way endothelial cells find their paths through tissue while forming small blood vessels.
9. Pipp F., Heil M., Issbrucker K., Ziegelhoeffer T., Martin S., van den Heuvel J., Weich H., Fernandez B., Golomb G., Carmeliet P., et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res 92 (2003) 378-385
10. Babiak A., Schumm A.M., Wangler C., Loukas M., Wu J., Dombrowski S., Matuschek C., Kotzerke J., Dehio C., and Waltenberger J. Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion. Cardiovasc Res 61 (2004) 789-795
11. Robinson C.J., and Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114 (2001) 853-865
12. Yu J., Lei L., Liang Y., Hinh L., Hickey R.P., Huang Y., Liu D., Yeh J.L., Rebar E., Case C., et al. An engineered VEGF-activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced-age mice. FASEB J 20 (2006) 479-481
13. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 15 (2004) 215-228
14. Hao X., Mansson-Broberg A., Gustafsson T., Grinnemo K.H., Blomberg P., Siddiqui A.J., Wardell E., and Sylven C. Angiogenic effects of dual gene transfer of bFGF and PDGF-BB after myocardial infarction. Biochem Biophys Res Commun 315 (2004) 1058-1063
15. Morishita R., Aoki M., Hashiya N., Yamasaki K., Kurinami H., Shimizu S., Makino H., Takesya Y., Azuma J., and Ogihara T. Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 4 (2004) 199-206
16. Powell R.J., Dormandy J., Simons M., Morishita R., and Annex B.H. Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial. Vasc Med 9 (2004) 193-198
17. Zhong J., Eliceiri B., Stupack D., Penta K., Sakamoto G., Quertermous T., Coleman M., Boudreau N., and Varner J.A. Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J Clin Invest 112 (2003) 30-41
18. Hou D., Maclaughlin F., Thiesse M., Panchal V.R., Bekkers B.C., Wilson E.A., Rogers P.I., Coleman M.C., and March K.L. Widespread regional myocardial transfection by plasmid encoding Del-1 following retrograde coronary venous delivery. Catheter Cardiovasc Interv 58 (2003) 207-211
19. Rajagopalan S., Olin J.W., Young S., Erikson M., Grossman P.M., Mendelsohn F.O., Regensteiner J.G., Hiatt W.R., and Annex B.H. Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther 15 (2004) 619-624
20. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88 (2000) 1474-1480
21. Rivard A., Berthou-Soulie L., Principe N., Kearney M., Curry C., Branellec D., Semenza G.L., and Isner J.M. Age-dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity. J Biol Chem 275 (2000) 29643-29647
22. Schultz A., Lavie L., Hochberg I., Beyar R., Stone T., Skorecki K., Lavie P., Roguin A., and Levy A.P. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 100 (1999) 547-552
23. Post M.J., Sato K., Murakami M., Bao J., Tirziu D., Pearlman J.D., and Simons M. Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation. Am J Physiol Regul Integr Comp Physiol 290 (2006) R494-R500
24. Cox C.M., D'Agostino S.L., Miller M.K., Heimark R.L., and Krieg P.A. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 296 (2006) 177-189
25. Walter D.H., and Dimmeler S. Endothelial progenitor cells: regulation and contribution to adult neovascularization. Herz 27 (2002) 579-588
26. Dor Y., Djonov V., Abramovitch R., Itin A., Fishman G.I., Carmeliet P., Goelman G., and Keshet E. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 21 (2002) 1939-1947
27. Ozawa C.R., Banfi A., Glazer N.L., Thurston G., Springer M.L., Kraft P.E., McDonald D.M., and Blau H.M. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 113 (2004) 516-527
28. Ehrbar M., Djonov V.G., Schnell C., Tschanz S.A., Martiny-Baron G., Schenk U., Wood J., Burri P.H., Hubbell J.A., and Zisch A.H. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res 94 (2004) 1124-1132
29. Yao C., Prevel P., Koch S., Schenck P., Noah E.M., Pallua N., and Steffens G. Modification of collagen matrices for enhancing angiogenesis. Cells Tissues Organs 178 (2004) 189-196
30. Richardson T.P., Peters M.C., Ennett A.B., and Mooney D.J. Polymeric system for dual growth factor delivery. Nat Biotechnol 19 (2001) 1029-1034
31. Sun Q., Chen R.R., Shen Y., Mooney D.J., Rajagopalan S., and Grossman P.M. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm Res 22 (2005) 1110-1116
32. Post M.J., Pawliuk R., Leboulch P., Arbuckle B., Palac R.T., Beaver T., Kiorpes T., Spaltro J., and Simons M. Intramyocardial slow release PDGF-BB dose dependently improves perfusion and function in a pig model of cardiac ischemia. Circulation 106 Suppl II (2002) II-37
33. Laham R.J., Sellke F.W., Edelman E.R., Pearlman J.D., Ware J.A., Brown D.L., Gold J.P., and Simons M. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100 (1999) 1865-1871
34. Szulc J., Wiznerowicz M., Sauvain M.O., Trono D., and Aebischer P. A versatile tool for conditional gene expression and knockdown. Nat Methods 3 (2006) 109-116
35. Luo Z., Diaco M., Murohara T., Ferrara N., Isner J.M., and Symes J.F. Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury. Ann Thorac Surg 64 (1997) 993-998
36. Poole T.J., Finkelstein E.B., and Cox C.M. The role of FGF and VEGF in angioblast induction and migration during vascular development. Dev Dyn 220 (2001) 1-17
37. House S.L., Bolte C., Zhou M., Doetschman T., Klevitsky R., Newman G., and Schultz Jel J. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 108 (2003) 3140-3148
38. Yasuda S., Goto Y., Baba T., Satoh T., Sumida H., Miyazaki S., and Nonogi H. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol 36 (2000) 115-121
39. Nakamura T., Mizuno S., Matsumoto K., Sawa Y., Matsuda H., and Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 106 (2000) 1511-1519
40. Morimoto H., Takahashi M., Izawa A., Ise H., Hongo M., Kolattukudy P.E., and Ikeda U. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res 99 (2006) 891-899
41. Fujiyama S., Amano K., Uehira K., Yoshida M., Nishiwaki Y., Nozawa Y., Jin D., Takai S., Miyazaki M., Egashira K., et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ Res 93 (2003) 980-989
42. Ueda K., Takano H., Hasegawa H., Niitsuma Y., Qin Y., Ohtsuka M., and Komuro I. Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Akt-endothelial NO synthase pathway. Arterioscler Thromb Vasc Biol 26 (2006) e108-e113
43. Kanellakis P., Slater N.J., Du X.J., Bobik A., and Curtis D.J. Granulocyte colony-stimulating factor and stem cell factor improve endogenous repair after myocardial infarction. Cardiovasc Res 70 (2006) 117-125
44. Goumans M.J., Zwijsen A., van Rooijen M.A., Huylebroeck D., Roelen B.A., and Mummery C.L. Transforming growth factor-beta signalling in extraembryonic mesoderm is required for yolk sac vasculogenesis in mice. Development 126 (1999) 3473-3483